{"filing":{"accession_number":"0001171843-26-006225","cik":"0001574232","ticker":"ADXN","company_name":"Addex Therapeutics Ltd.","form":"6-K","filing_date":"2026-09-25","report_date":"2026-09-25","primary_document":"f6k_092526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1574232/000117184326006225/f6k_092526.htm"},"events":[{"id":34992,"run_id":32222,"accession_number":"0001171843-26-006225","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Addex has regained full global rights to its GABAB positive allosteric modulator portfolio from Indivior following Indivior's R\u0026D rationalization and planned merger with Supernus Pharmaceuticals. This represents a material change in the company's asset portfolio and intellectual property rights—the return of a development candidate for substance use disorders plus freedom to pursue additional therapeutic indications. The CEO explicitly states this gives Addex \"the flexibility to advance our broader GABAB PAM portfolio independently\" and \"one of the broadest portfolios targeting GABAB receptor biology,\" indicating a significant strategic repositioning of the company's pipeline and competitive position.","company_name":"Addex Therapeutics Ltd.","ticker":"ADXN","filing_date":"2026-09-25","form":"6-K","submitted_at":null,"items":[{"id":38897,"accession_number":"0001171843-26-006225","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Addex has regained full global rights to its GABAB positive allosteric modulator portfolio from Indivior following Indivior's R\u0026D rationalization and planned merger with Supernus Pharmaceuticals. This represents a material change in the company's asset portfolio and intellectual property rights—the return of a development candidate for substance use disorders plus freedom to pursue additional therapeutic indications. The CEO explicitly states this gives Addex \"the flexibility to advance our broader GABAB PAM portfolio independently\" and \"one of the broadest portfolios targeting GABAB receptor biology,\" indicating a significant strategic repositioning of the company's pipeline and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-25T10:05:52.183532+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38897,"accession_number":"0001171843-26-006225","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Addex has regained full global rights to its GABAB positive allosteric modulator portfolio from Indivior following Indivior's R\u0026D rationalization and planned merger with Supernus Pharmaceuticals. This represents a material change in the company's asset portfolio and intellectual property rights—the return of a development candidate for substance use disorders plus freedom to pursue additional therapeutic indications. The CEO explicitly states this gives Addex \"the flexibility to advance our broader GABAB PAM portfolio independently\" and \"one of the broadest portfolios targeting GABAB receptor biology,\" indicating a significant strategic repositioning of the company's pipeline and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-25T10:05:52.183532+00:00","company_name":"Addex Therapeutics Ltd.","ticker":"ADXN","filing_date":"2026-09-25"}]}